Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Imago BioSciences, Inc. (IMGO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2023 |
SC 13G/A
| Farallon Capital Partners, L.P. reports a 0% stake in Imago BioSciences, Inc. |
| 01/26/2023 |
SC 13G/A
| BlackRock Inc. reports a 13.2% stake in IMAGO BIOSCIENCES INC |
| 01/23/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 01/20/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/17/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/12/2023 |
SC 13D/A
| Clarus Lifesciences III, L.P. reports a 0% stake in Imago BioSciences, Inc. |
| 01/11/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 01/11/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/11/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/11/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 01/11/2023 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 01/11/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 01/11/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 01/03/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 12/21/2022 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 12/21/2022 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 12/12/2022 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 11/21/2022 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 11/21/2022 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 11/21/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Agreement and Plan of Merger, among Merck Sharp & Dohme LLC, M-Inspire Merger Sub, Inc. and Imago BioSciences, Inc",
"Form of Tender and Support Agreement, by and among Merck Sharp & Dohme LLC, M-Inspire, Merger Sub, Inc. and certain stockholders of Imago BioSciences, Inc",
"Merck to Acquire Imago BioSciences, Inc. Acquisition expands Merck's growing hematology portfolio" |
|
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Quarterly results|
Docs:
|
"Condensed Consolidated Balance Sheets September 30, December 31, 2022 2021 ASSETS Current assets: Cash and cash equivalents $ 7,293 $ 11,226 Short-term investments 171,121 206,184 Prepaid expenses and other current assets 3,626 3,894 Total current assets 182,040 221,304 Property and equipment, net 2 2 Other long-term assets 4,415 3,480 Total assets $ 186,457 $ 224,786 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 3,898 $ 3,459 Accrued research and development expenses 6,823 4,213 Accrued and other current liabilities 3,117 2,420 Total current liabilities 13,838 10,092 Commitments and contingencies Stockholders’ equity: Common stock, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 33,815,999 and 33,531,743 shar..." |
|
| 09/01/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/30/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/29/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/18/2022 |
8-K
| Quarterly results |
| 08/18/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/12/2022 |
8-K
| Quarterly results |
| 06/13/2022 |
8-K
| Quarterly results |
| 06/10/2022 |
8-K
| Quarterly results |
| 06/06/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
|
|
|